In the quest to develop more specific and safe pharmacological interventions to treat obesity, the recently presented molecular ultrastructure of human CB1 holds potential for newer opportunities for design of novel anti-obesity drugs [328,329]. This evidence concerns the gene CNR1 and obesity disorder.